GFAP and Alzheimer disease: Despite considerable improvements in plasma biomarker sensitivity with the advent of ultra‐sensitive immunoassays and advancement of mass spectrometry, plasma biomarkers – with the exception of plasma GFAP – remain less accurate than CSF biomarkers of the same molecule for discriminating individuals with AD pathological changes from those without.55, 56